Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Overall Market Size
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2021 VS 2028
2.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
3.2 Top Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Ranked by Revenue
3.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies
3.4 Top 3 and Top 5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
3.6.1 List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Markets, 2021 & 2028
4.1.2 Intravenous
4.1.3 Oral
4.1.4 Subcutaneous
4.1.5 Others
4.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
4.2.1 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
4.2.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
4.2.3 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
5.2.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
5.2.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
5.2.3 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028
6.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
6.2.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
6.2.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
6.2.3 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
6.3.2 US Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
6.4.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.4 U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.5 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.6 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.7 Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.4.8 Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
6.5.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.5.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.5.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.5.5 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.5.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
6.6.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.6.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
6.7.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.7.3 Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.7.4 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
6.7.5 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
7 Players Profiles
7.1 F. Hoffmann-La Roche Ltd
7.1.1 F. Hoffmann-La Roche Ltd Corporate Summary
7.1.2 F. Hoffmann-La Roche Ltd Business Overview
7.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.1.5 F. Hoffmann-La Roche Ltd Key News
7.2 Alexion Pharmaceuticals
7.2.1 Alexion Pharmaceuticals Corporate Summary
7.2.2 Alexion Pharmaceuticals Business Overview
7.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.2.5 Alexion Pharmaceuticals Key News
7.3 RemeGen
7.3.1 RemeGen Corporate Summary
7.3.2 RemeGen Business Overview
7.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.3.5 RemeGen Key News
7.4 Nihon Pharmaceutical
7.4.1 Nihon Pharmaceutical Corporate Summary
7.4.2 Nihon Pharmaceutical Business Overview
7.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.4.5 Nihon Pharmaceutical Key News
7.5 Harbour BioMed
7.5.1 Harbour BioMed Corporate Summary
7.5.2 Harbour BioMed Business Overview
7.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.5.5 Harbour BioMed Key News
7.6 Lundbeck
7.6.1 Lundbeck Corporate Summary
7.6.2 Lundbeck Business Overview
7.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.6.5 Lundbeck Key News
7.7 Bionure
7.7.1 Bionure Corporate Summary
7.7.2 Bionure Business Overview
7.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.7.5 Bionure Key News
7.8 Opexa Therapeutics
7.8.1 Opexa Therapeutics Corporate Summary
7.8.2 Opexa Therapeutics Business Overview
7.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.8.5 Opexa Therapeutics Key News
7.9 TG Therapeutics
7.9.1 TG Therapeutics Corporate Summary
7.9.2 TG Therapeutics Business Overview
7.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.9.5 TG Therapeutics Key News
7.10 Bio-Thera Solutions
7.10.1 Bio-Thera Solutions Corporate Summary
7.10.2 Bio-Thera Solutions Business Overview
7.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.10.5 Bio-Thera Solutions Key News
7.11 Boston Pharmaceuticals
7.11.1 Boston Pharmaceuticals Corporate Summary
7.11.2 Boston Pharmaceuticals Business Overview
7.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.11.5 Boston Pharmaceuticals Key News
7.12 Cour Pharmaceutical
7.12.1 Cour Pharmaceutical Corporate Summary
7.12.2 Cour Pharmaceutical Business Overview
7.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
7.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
7.12.5 Cour Pharmaceutical Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer